Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight to Decode MET-Driven Biology and Resistance in Advanced NSCLC
Data include assessment of MET expression, tumor and immune pathway activity, and…
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and…
Johnson & Johnson’s Phase 3 prostate cancer study shows ERLEADA (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm
Compared with patients receiving hormone therapy alone, patients were nine times more…
Nokia Corporation – Managers’ transactions (Hanrahan)
May 31, 2026 06:00 ET | Source: Nokia Oyj Nokia CorporationManagers’ transactions31…
Crypto News Today: AlphaPepe Hits $1.38M Raised While Bitcoin Price Prediction Targets $250K
MONACO, May 30, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning…
![Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About](https://i3.wp.com/ml.globenewswire.com/Resource/Download/ae83c67f-909d-4427-80c0-3bc4826dfd96?w=420&resize=420,280&ssl=1 "Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About")
Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About
New York City, NY, May 30, 2026 (GLOBE NEWSWIRE) -- The global…
ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026
Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time…
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and…
ImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026
– Updated data across two dose levels of 200 mW/cm and 400…
Fobi AI Provides Corporate Update Regarding FFCTO Revocation Process and Q3 Interim Filings
May 29, 2026 21:18 ET | Source: Fobi AI Inc. VANCOUVER, BC,…
